From Nasdaq: 2024-06-10 00:52:24

Eli Lilly stock (NYSE: LLY) has surged 400% from $170 to $840 since early 2021, outperforming peers like Pfizer and Johnson & Johnson. This rise is driven by a 273% increase in the P/S ratio, a 39% revenue jump to $39 billion, and a 5% increase in shares outstanding.

LLY stock has consistently outperformed the S&P 500 in recent years, with returns of 64% in 2021, 32% in 2022, and 59% in 2023. While it may have priced in most positives, further developments in its pipeline and drug sales could drive it higher.

Eli Lilly’s revenues increased by 39% from $35 billion in 2020 to $49 billion in 2023. The company is expected to see explosive growth in its diabetes and obesity drugs, with anticipated peak sales of $50 billion. Market share gains have also contributed to this growth.

Investors are attracted to LLY stock’s solid pipeline potential, particularly in the obesity drug market. While some positives may be priced in, future market share gains and regulatory approvals could drive further growth in the stock price.

Despite a potential dip, the long-term outlook for LLY stock remains positive, given the expected rise in the obesity drugs market dominated by Eli Lilly and Novo Nordisk. Any setbacks should be seen as opportunities for future gains.

Eli Lilly’s stock has returned 2% in June 2024, 44% year-to-date, and a total of 1038% from 2017 to 2024, outperforming the S&P 500 and the Trefis Reinforced Value Portfolio. Consider investing in Trefis Market-Beating Portfolios for superior returns.

Invest with confidence in Trefis Market-Beating Portfolios for superior returns compared to the S&P 500. Explore all Trefis Price Estimates for valuable insights into various industries and companies. Remember, past performance is not indicative of future results.



Read more at Nasdaq: Up 400% In Three Years Eli Lilly Stock Just Keeps Giving